<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04753749</url>
  </required_header>
  <id_info>
    <org_study_id>SFHI01</org_study_id>
    <nct_id>NCT04753749</nct_id>
  </id_info>
  <brief_title>Evaluation of a Modified Anti-Platelet Therapy Associated With Low-dose DES Firehawk in Acute Myocardial Infarction Patients Treated With Complete Revascularization Strategy</brief_title>
  <acronym>TARGET FIRST</acronym>
  <official_title>Evaluation of a Modified Anti-Platelet Therapy Associated With Low-dose DES Firehawk in Acute Myocardial Infarction Patients Treated With Complete Revascularization Strategy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MicroPort CRM</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MicroPort CRM</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to evaluate a modified antiplatelet therapy associated with Firehawk low-dose&#xD;
      rapamycin DES in acute myocardial infarction patients treated with complete revascularization&#xD;
      strategy. The modified antiplatelet therapy consists of a reduced duration of Dual&#xD;
      Antiplatelet Therapy post procedure (ie. 1 month duration) followed by P2Y12 inhibitor&#xD;
      monotherapy for the next 11 months. It is hypothesized that in the setting of clinically&#xD;
      stable, low to moderate complexity acute Myocardial Infarction patients, a modern approach&#xD;
      combining a stent with high biocompatibility feature, complete revascularization strategy and&#xD;
      modified antiplatelet therapy may be associated with similar outcomes, or even a significant&#xD;
      benefit compared with guidelines-recommended 12-month DAPT. This benefit could be driven by a&#xD;
      reduced risk in significant bleeding events, while keeping a comparable protection against&#xD;
      ischemic risk. Enrolled subjects will be randomized in a 1:1 ratio to either cessation of&#xD;
      aspirin at 1 months, either continuation of DAPT. Selection of the P2Y12 inhibitor agent is&#xD;
      left to investigator judgment but has to be in line with the current ESC guidelines. Subjects&#xD;
      treated with the Firehawk or Firehawk Liberty coronary stent will be included in this study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2021</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Net Adverse Clinical and Cerebral Events (NACCE)</measure>
    <time_frame>11 months post randomization</time_frame>
    <description>(Number of participants with first occurrence of) NACCE, defined as a composite of all cause death, non-fatal myocardial infarction, definite/probable stent thrombosis, stroke, or bleeding events (BARC type 3 or 5)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bleeding events</measure>
    <time_frame>11 months post randomization</time_frame>
    <description>(Number of participants with first occurrence of) bleeding events (BARC 2,3 or 5)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2246</enrollment>
  <condition>Myocardial Infarction, Acute</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Shortened DAPT followed by P2Y12 inhibitor monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dual Antiplatelet Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Shortened DAPT followed by P2Y12 inhibitor monotherapy (cessation of aspirin)</intervention_name>
    <description>Subjects will receive DAPT during 1 month post procedure, followed by P2Y12 inhibitor monotherapy (cessation of aspirin) for the next 11 months</description>
    <arm_group_label>Shortened DAPT followed by P2Y12 inhibitor monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard DAPT</intervention_name>
    <description>Subjects will receive standard treatment: P2Y12 inhibitor and aspirin (DAPT) during 12 months after procedure</description>
    <arm_group_label>Dual Antiplatelet Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (General):&#xD;
&#xD;
          -  Troponin-positive Non-ST-Elevation MI, requiring early invasive treatment (PCI), or&#xD;
             ST-Elevation MI requiring primary PCI, and PCI occurred within the last 7 days&#xD;
&#xD;
          -  Subject is eligible for per-protocol antiplatelet treatments&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Inclusion Criteria (Procedural/angiographic):&#xD;
&#xD;
          -  Successful revascularization&#xD;
&#xD;
          -  All treated lesions:&#xD;
&#xD;
               -  In native coronary arteries only&#xD;
&#xD;
               -  In vessels with visual reference diameter ≥2.25 mm and ≤ 4.00 mm&#xD;
&#xD;
               -  Implanted with the study device&#xD;
&#xD;
               -  Maximum 3 lesions treated (*)&#xD;
&#xD;
               -  Maximum total stent length ≤ 80 mm&#xD;
&#xD;
          -  Complete revascularization performed when more than 1 significant lesion, during the&#xD;
             index procedure or in staged procedure(s) occurring within 7 days from the index&#xD;
             procedure.&#xD;
&#xD;
        Exclusion Criteria (General):&#xD;
&#xD;
          -  Subjects with prior STEMI or prior PCI within 12 months before index admission&#xD;
&#xD;
          -  Prior Coronary Artery Bypass Graft (CABG) Surgery&#xD;
&#xD;
          -  Cardiogenic shock&#xD;
&#xD;
          -  Secondary PCI&#xD;
&#xD;
          -  Fibrinolysis&#xD;
&#xD;
          -  Prior stent thrombosis&#xD;
&#xD;
          -  Planned PCI, CABG, or surgery within 12 months&#xD;
&#xD;
          -  Need for Oral Anti-Coagulation therapy&#xD;
&#xD;
          -  Ischemic stroke or ICH within 12 months&#xD;
&#xD;
          -  eGFR &lt;30 mL/min/1.73 m2 or dialysis&#xD;
&#xD;
          -  Active bleeding at time of inclusion or high risk for major bleeding&#xD;
&#xD;
          -  History of bleeding diathesis or coagulopathy or subject refuse blood transfusions&#xD;
&#xD;
          -  Stage B or C liver cirrhosis or active cancer within 12 months&#xD;
&#xD;
          -  Baseline haemoglobin &lt;13 g/dL (12g/dL for women) or anaemia requiring transfusion in&#xD;
             the 4 weeks prior to index procedure&#xD;
&#xD;
          -  Moderate or severe thrombocytopenia&#xD;
&#xD;
          -  Expected non-adherence to protocol or estimated life expectancy ≤12 months&#xD;
&#xD;
          -  Known hypersensitivity or contraindication to any medication used in the study or any&#xD;
             of the study stent's components/compounds&#xD;
&#xD;
          -  Participation in another interventional clinical trial&#xD;
&#xD;
          -  Woman who is pregnant, nursing or with known intention to procreate&#xD;
&#xD;
        Exclusion Criteria (Procedural/Angiographic):&#xD;
&#xD;
          -  In-stent restenosis or thrombosis&#xD;
&#xD;
          -  Chronic total occlusion&#xD;
&#xD;
          -  Severe calcification&#xD;
&#xD;
          -  True bifurcation disease and side branch diameter ≥ 2mm, or bifurcation treated with 2&#xD;
             stents&#xD;
&#xD;
          -  Left main coronary artery lesion&#xD;
&#xD;
          -  Residual untreated dissection ≥ C&#xD;
&#xD;
          -  Implantation of a non-study stent&#xD;
&#xD;
          -  Subject is deemed to receive preferentially CABG within 1 year&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giuseppe Tarantini</last_name>
    <role>Principal Investigator</role>
    <affiliation>Padova University Hospital, Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Bouchez</last_name>
    <email>david.bouchez@crm.microport.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yann Poezevara</last_name>
    <email>yann.poezevara@crm.microport.com</email>
  </overall_contact_backup>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 8, 2021</study_first_submitted>
  <study_first_submitted_qc>February 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2021</study_first_posted>
  <last_update_submitted>February 12, 2021</last_update_submitted>
  <last_update_submitted_qc>February 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

